Viveta inhaled treprostinil: Final Phase III data

Final data from the Phase III TRIUMPH-1 trial in 235 patients with severe PAH showed a 20-meter improvement in 6MW distance at week 12 for Viveta vs. placebo (p<0.0006). Patients receiving Viveta also...